This is a Phase 1b study conducted in multiple countries, including the US, the UK, and the Netherlands aiming to better understand the safety of an oral drug in a capsule form which includes a substance called NLRP3 inhibitor. The study aims to understand how the NLRP3 inhibitor affects the body and brain of people with Parkinson’s disease. The NLRP3 inhibitor drug tested in this study has been studied in healthy participants previously and showed a favorable safety profile, however, it will be the first time it will be studied in people with Parkinson’s disease.